Taxotere, Docetaxel Newswire (Page 8)

Taxotere, Docetaxel Newswire (Page 8)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 8)

Results 141 - 160 of 1,015 in Taxotere, Docetaxel (generic)

  1. FDA Approves Genentech's Cancer Immunotherapy Tecentriq...Read the original story w/Photo

    Oct 17, 2016 | Drugs.com

    October 18, 2016 -- Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration approved Tecentriq for the treatment of people with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities. This approval is based on results from the randomized Phase III OAK and Phase II POPLAR studies.

    Comment?

  2. FDA OKs new use for Roche's TecentriqRead the original story w/Photo

    Oct 18, 2016 | Seeking Alpha

    The FDA approves the use of Roche's TECENTRIQ for the treatment of patients with metastatic non-small cell lung cancer who have progressed during or following platinum-based chemotherapy and have progressed on an appropriate FDA-approved targeted therapy if their tumor was EGFR- or ALK-positive. Results from the Phase 3 OAK study showed NSCLC patients treated with atezolizumab lived a median of 4.2 months longer than those treated with docetaxel chemo with 27% less risk of death or cancer progression.

    Comment?

  3. Endocyte Inc. (ECYT) Downgraded by Zacks Investment Research to "Hold"Read the original story w/Photo

    Oct 18, 2016 | AmericanBankingNews.com

    According to Zacks, "Endocyte is a development-stage biopharmaceutical company, focused on the development of therapies for cancer and inflammatory diseases. The company uses its proprietary technology platform to develop various new small-molecule drug conjugates for a range of diseases.

    Comment?

  4. Investment Analysts' Downgrades for October, 18th (ALK, CSIQ, CTRN, ...Read the original story w/Photo

    Oct 18, 2016 | AmericanBankingNews.com

    According to Zacks, "Alaska Air Group continues to be impacted by volatile fuel prices and risk of low demand. With the holiday season getting over in U.S., the company might face challenges in improving its top-line growth.

    Comment?

  5. OncoGenex's custirsen comes up short in late-stage lung cancer study; shares down 6%Read the original story w/Photo

    Oct 13, 2016 | Seeking Alpha

    Thinly traded nano cap OncoGenex eases in early trading after reporting failed results from a Phase 3 clinical trial, ENSPIRIT, assessing lead product candidate custirsen, in combination with the chemo agent docetaxel, in patients with advanced non-small cell lung cancer who had progressed after initial chemotherapy. The combination failed to demonstrate a statistically valid increase in median overall survival compared to docetaxel alone .

    Comment?

  6. OncoGenex Announces Results from the Phase 3 ENSPIRIT Trial of...Read the original story w/Photo

    Oct 13, 2016 | Canada NewsWire

    The trial did not meet the primary endpoint of demonstrating a statistically significant improvement in overall survival for patients treated with custirsen in combination with docetaxel compared to docetaxel alone. The median overall survival for the custirsen arm was 9.0 months versus 7.9 months for the control arm with a hazard ratio of 0.915 .

    Comment?

  7. Tumor suppressor protein DAB2IP participates in chromosomal stability ...Read the original story

    Oct 12, 2016 | Nucleic Acids Research

    Tel: +1 214 648 1263; Fax: +1 214 648 5995; Email: Defects in kinetochore-microtubule attachment and the spindle assembly checkpoint during cell division are strongly associated with chromosomal instability . CIN has been linked to carcinogenesis, metastasis, poor prognosis and resistance to cancer therapy.

    Comment?

  8. Nordic Nanovector Announces The Appointment Of MD As Non-Executive Board DirectorRead the original story

    Oct 11, 2016 | BioSpace

    Oslo, Norway, 12 October 2016 Nordic Nanovector ASA announces that Joanna Horobin was elected to its Board as Non-executive Director at the company's Extraordinary General Meeting held today in Oslo, Norway. Dr Horobin replaces Dr Renee P Tannenbaum who stepped down from the Board of Directors today for personal reasons.

    Comment?

  9. Nordic Nanovector Announces the Appointment of Joanna Horobin, MD, as Non-Executive Board DirectorRead the original story w/Photo

    Oct 12, 2016 | Freshnews

    Nordic Nanovector ASA announces that Joanna Horobin was elected to its Board as Non-executive Director at the company's Extraordinary General Meeting held today in Oslo, Norway. Dr Horobin replaces Dr Renee P Tannenbaum who stepped down from the Board of Directors today for personal reasons.

    Comment?

  10. Neem plant compound could suppress development of prostate cancer: Singapore studyRead the original story w/Photo

    Oct 12, 2016 | NutraIngredients

    Nimbolide, a bioactive terpenoid compound derived from Azadirachta indica, more commonly known as the neem plant, could reduce the size of prostate tumours by up to 70 per cent and suppress its spread or metastasis by half, say Singapore academics. A team of international researchers led by Associate Professor Gautam Sethi from the Department of Pharmacology at the Yong Loo Lin School of Medicine at the National University of Singapore reported the findings following a 12-week study on mice.

    Comment?

  11. Custirsen shows no survival benefits in metastatic prostate cancerRead the original story w/Photo

    Oct 12, 2016 | Medical News Today

    A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone in patients with previously-treated metastatic, castration-resistant prostate cancer has shown no significant survival gains compared to cabazitaxel/prednisone alone, according to data presented at the ESMO 2016 Congress in Copenhagen1. "Despite the negative outcome of the trial, the evaluation of custirsen in prostate cancer was conducted on the basis of solid preclinical and clinical evidence supporting anti-tumour activity," said principal investigator Professor Karim Fizazi, head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France.

    Comment?

  12. MEK inhibition in KRAS-mutant non-small-cell lung cancer (NSCLC) did not improve survivalRead the original story w/Photo

    Oct 12, 2016 | Medical News Today

    MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer , according to data presented at the ESMO 2016 Congress in Copenhagen1. "KRAS-mutant lung cancer is the largest genomically defined subset of lung cancer where we do not have effective targeted therapies," said principal investigator Dr Pasi Janne, from the Dana-Farber Cancer Institute in Boston, US.

    Comment?

  13. Greater patient selection may be needed for first line nivolumab to improve progression-free survivalRead the original story w/Photo

    Oct 11, 2016 | PhysOrg Weblog

    Greater patient selection may be needed for first line nivolumab to improve progression-free survival over chemotherapy in advanced lung cancer as the CheckMate 026 trial gave negative results in a broad group of patients expressing PD-L1 in their tumour cells. The findings were presented at the ESMO 2016 Congress in Copenhagen.

    Comment?

  14. Greater patient selection may be needed for first line nivolumab to...Read the original story w/Photo

    Oct 11, 2016 | Medical News Today

    Greater patient selection may be needed for first line nivolumab to improve progression-free survival over chemotherapy in advanced lung cancer as the CheckMate 026 trial gave negative results in a broad group of patients expressing PD-L1 in their tumour cells. The findings were presented at the ESMO 2016 Congress in Copenhagen.1 "Nivolumab represents a standard of care in the second-line treatment of advanced non-small cell lung cancer as it improved overall survival compared to docetaxel in phase III trials in these patients," said lead author Dr Mark A. Socinski, Executive Medical Director, Florida Hospital Cancer Institute, US.

    Comment?

  15. Significant survival gains with atezolizumab vs docetaxel for non-small-cell lung cancerRead the original story w/Photo

    Oct 11, 2016 | Medical News Today

    The first phase III study of PD-L1 inhibitor atezolizumab in previously-treated non-small-cell lung cancer has seen significant improvements in survival compared to standard chemotherapy , researchers reported at the ESMO 2016 Congress in Copenhagen.1 PD-L1 inhibitors are of a class of cancer immunotherapies called checkpoint inhibitors, and work by inhibiting one of the mechanisms of resistance developed by cancer cells in order to evade the immune system.

    Comment?

  16. Ceritinib provides longer progression-free survival than chemotherapy ...Read the original story w/Photo

    Oct 11, 2016 | Medical News Today

    Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study presented at the ESMO 2016 Congress in Copenhagen.1 "Patients with non-small cell lung cancer should receive front line therapy with the anaplastic lymphoma kinase inhibitor crizotinib," said lead author Professor Giorgio Scagliotti, head of the Department of Oncology, University of Turin, Italy. "Most patients develop resistance to crizotinib and currently second line treatment is represented by chemotherapy alone."

    Comment?

  17. Significant survival gains from neoadjuvant chemotherapy for high-risk soft tissue sarcomaRead the original story w/Photo

    Oct 11, 2016 | Medical News Today

    Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim analysis that led to the early discontinuation of a trial presented at the ESMO 2016 Congress in Copenhagen.1 "The benefit of adjuvant chemotherapy in soft tissue sarcoma has been debated a lot over recent years because of contradictory study outcomes," said principal investigator Dr Alessandro Gronchi, Chair of the Sarcoma Surgery at the National Cancer Institute, Milan, Italy.

    Comment?

  18. MEK inhibition in KRAS-mutant NSCLC did not improve survivalRead the original story w/Photo

    Oct 9, 2016 | EurekAlert!

    MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer , according to data presented at the ESMO 2016 Congress in Copenhagen1. "KRAS-mutant lung cancer is the largest genomically defined subset of lung cancer where we do not have effective targeted therapies," said principal investigator Dr Pasi Janne, from the Dana-Farber Cancer Institute in Boston, US.

    Comment?

  19. Endocyte Inc. (ECYT) Upgraded by Zacks Investment Research to "Buy"Read the original story w/Photo

    Oct 8, 2016 | AmericanBankingNews.com

    The firm presently has a $3.75 target price on the biopharmaceutical company's stock. Zacks Investment Research's target price indicates a potential upside of 19.43% from the company's current price.

    Comment?

  20. A phase I study of nedaplatin, pemetrexed and thoracic...Read the original story w/Photo

    Oct 6, 2016 | BioMed Central

    Concurrent chemotherapy and radiation is the standard treatment for unresectable stage III Lung adenocarcinoma. However, no optimal concurrent chemotherapeutic regimen has been described.

    Comment?